<DOC>
	<DOCNO>NCT01463163</DOCNO>
	<brief_summary>This single-center , randomize , single-blind , investigator-initiated , pharmacodynamic study parallel design . Patients ST elevation myocardial infarction , undergo primary percutaneous coronary intervention randomize informed consent , 1:1 ratio follow treatment group : Group Α : Ticagrelor 180mg loading dose ( LD ) , follow 90mg x2 maintenance dose ( MD ) start 12±6 hour post LD , Day 5 ( 5 day randomization ) Group Β : Prasugrel 60 mg LD follow 10mg x1 MD start 24 hour post LD , Day 5 ( 5 day randomization ) . Platelet reactivity assessment perform randomization ( Hour 0 ) 1 , 2 , 6 , 24 hour randomization , Day 5 . Documentation major adverse cardiac event ( death , myocardial infarction , stroke , revascularization procedure PCI CABG ) serious adverse event ( bleed , adverse event ) perform Day 5 .</brief_summary>
	<brief_title>Ticagrelor Comparison Prasugrel Early Inhibition Platelet Reactivity Patients With ST-elevation Myocardial Infarction ( STEMI ) , Undergoing Primary Percutaneous Coronary Intervention ( PCI )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Age ≥18 year old 2 . Patients STEMI undergo primary PCI stenting 3 . Informed consent obtain write Pregnancy Breastfeeding Inability give inform consent high likelihood unavailable Day 5 Prior PCI perform within 30 day prior randomization Cardiogenic shock Major periprocedural complication ( death , stent thrombosis , vessel perforation , arrhythmia require cardioversion , temporary pacemaker insertion intravenous antiarrhythmic agent , respiratory failure require intubation , vascular injury ( arteriovenous shunt , retroperitoneal bleed ) , major bleeding ( need bood transfusion drop haemoglobin postPCI ≥ 5 gr/ dl intracranial bleeding ) . Unsuccessful PCI ( residual stenosis &gt; 30 % flow &lt; ΤΙΜΙ 3 ) plan stag PCI next 5 day randomization Requirement oral anticoagulant prior Day 5 visit Current plan therapy thienopyridine class ADP receptor inhibitor . Known hypersensitivity prasugrel ticagrelor History gastrointestinal bleeding , genitourinary bleeding site abnormal bleeding within previous 6 month . Other bleed diathesis , consider investigator high risk bleeding . Any previous history ischemic stroke , intracranial hemorrhage disease ( neoplasm , arteriovenous malformation , aneurysm ) . Thombocytopenia ( &lt; 100.000 / μL ) randomization Anaemia ( Hct &lt; 30 % ) randomization Polycytaemia ( Hct &gt; 52 % ) randomization Periprocedural IIb/IIIa inhibitor administration Severe allergy contrast agent , unfractionated heparin , enoxaparin bivalirudin adequately premedicated . Recent ( &lt; 6 week ) major surgery trauma , include GABG . Subjects receive daily treatment nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitor discontinue duration study . Concomitant oral IV therapy strong CY P3A inhibitor ( ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazana vir , grapefruit juice N1 L/d ) , CYP3A substrates narrow therapeutic index ( cyclosporine , quinidine ) , strong CYP3A inducer ( rifampin /rifampicin , phenytoin , carbamazepine ) . Increased risk bradycardiac event . Dialysis require . Severe uncontrolled chronic obstructive pulmonary disease Known severe hepatic impairement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Platelet reactivity</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Prasugrel</keyword>
</DOC>